Long-term replacement of a mutated nonfunctional CNS gene: reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin.

Due to the complexity of brain function and the difficulty in monitoring alterations in neuronal gene expression, the potential of lentiviral gene therapy vectors to treat disorders of the CNS has been difficult to fully assess. In this study, we have assessed the utility of a third-generation equine infectious anemia virus (EIAV) in the Brattleboro rat model of diabetes insipidus, in which a mutation in the arginine vasopressin (AVP) gene results in the production of nonfunctional mutant AVP precursor protein. Importantly, by using this model it is possible to monitor the success of the gene therapy treatment by noninvasive assays. Injection of an EIAV-CMV-AVP vector into the supraoptic nuclei of the hypothalamus resulted in expression of functional AVP peptide in magnocellular neurons. This was accompanied by a 100% recovery in water homeostasis as assessed by daily water intake, urine production, and urine osmolality lasting for a 1-year measurement period. These data show that a single gene defect leading to a neurological disorder can be corrected with a lentiviral-based strategy. This study highlights the potential of using viral gene therapy for the long-term treatment of disorders of the CNS.

[1]  T. Hope,et al.  Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances Expression of Transgenes Delivered by Retroviral Vectors , 1999, Journal of Virology.

[2]  J. D. Neill,et al.  The Physiology of reproduction , 1988 .

[3]  Luc Montagnier,et al.  HIV-1 Genome Nuclear Import Is Mediated by a Central DNA Flap , 2000, Cell.

[4]  F. Gage,et al.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Philippe Colin,et al.  The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain , 2001, Nature Biotechnology.

[6]  H. Schmale,et al.  Structure and Expression of the Vasopressin Precursor Gene in Central Diabetes Insipidus a , 1993, Annals of the New York Academy of Sciences.

[7]  Y. Arsenijévic,et al.  Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. , 2000, Human gene therapy.

[8]  S. Lightman,et al.  Long-term gene therapy in the CNS: Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin , 1997, Nature Medicine.

[9]  N. Mazarakis,et al.  New methods to titrate EIAV-based lentiviral vectors. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  D. Trono.  Lentiviral vectors: turning a deadly foe into a therapeutic agent , 2000, Gene Therapy.

[11]  D. Pow,et al.  Immuno-electron microscopic evidence for two different types of partial somatic repair of the mutant Brattleboro vasopressin gene , 1992, Neuroscience.

[12]  S. Watson,et al.  Coordinate expression of hypothalamic pro-dynorphin and pro-vasopressin mRNAs with osmotic stimulation. , 1986, Neuroendocrinology.

[13]  A. Kingsman,et al.  Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. , 2001, Human molecular genetics.

[14]  A. Consiglio,et al.  In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice , 2001, Nature Medicine.

[15]  N. Blom,et al.  In Vivo Protection of Nigral Dopamine Neurons by Lentiviral Gene Transfer of the Novel GDNF-Family Member Neublastin/Artemin , 2000, Molecular and Cellular Neuroscience.

[16]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[17]  A. Kingsman,et al.  Stable gene transfer to the nervous system using a non-primate lentiviral vector , 1999, Gene Therapy.

[18]  J. Burbach,et al.  Differential responses to osmotic stress of vasopressin-neurophysin mRNA in hypothalamic nuclei. , 1984, Neuroendocrinology.

[19]  B. Harder,et al.  Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. , 2001, Human gene therapy.

[20]  J. Ridet,et al.  Lentiviral Vectors as a Gene Delivery System in the Mouse Midbrain: Cellular and Behavioral Improvements in a 6-OHDA Model of Parkinson's Disease Using GDNF , 2000, Experimental Neurology.